4.5 Article

Prevention and Treatment of Cancer-Related Infections, Version 2.2016

Journal

Publisher

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0093

Keywords

-

Categories

Funding

  1. Crucell
  2. NIH
  3. Janssen Pharmaceutical Products, LP
  4. Roche Laboratories, Inc.
  5. Merck Co., Inc.
  6. Rebiotix
  7. sanofi pasteur
  8. Astellas
  9. City of Hope
  10. Chimerix
  11. Gilead
  12. NeuralStem
  13. ViroPharma
  14. K-PAX Pharmaceuticals
  15. Allergan
  16. JMI Laboratories
  17. Ventrus
  18. Ansun
  19. HHS/ASPR
  20. NIAID Influenza Research Collaboration Social & Scientific Systems, Inc.
  21. Pfizer Inc.
  22. scynexis
  23. World Health Information Science Consultants
  24. GLG

Ask authors/readers for more resources

Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available